DocumentsDate added
Clinical study
*1Gulri A, 1Sood R, 2Dodwad V & 3Nagpal S
Affiliation:-
1Post graduate 2nd year, 2HOD & Professor, 3Post graduate 3rd year, Department of periodontics,I.T.S-CDSR ,Murad Nagar ,Ghaziabad,U.P, India.
Abstract:
Alendronate (ALN), an aminobisphosphonate,is known to inhibit osteoclastic bone resorption andwas proposed to have osteostimulative properties in vivo and in vitro as shown by an increase in matrix formation. The present study aims to explore the efficacy of a 1% ALNgel compared to a placebo gel as a local drug delivery system in adjunct to scaling and root planing (SRP) for the treatment of patients with chronic periodontitis.
A total of 20 sites with pocket depth of 4-6 mm were treated witha 1%ALN or placebo gel in adjunct to scaling and root planing. The ALN gel was prepared by adding ALN to a polyacrylic acid–distilled water mixture. Clinical parameters (gingival index, plaque index, probing depth [PD], and relative attachment level [RAL]) were recorded at baseline and 15 and 30 days.It was concluded that GI, PI , PPD , RAL is reduced in the test site where 1% ALN was placed in adjunct to scaling and root planning.
Key Words: Alendronate; Scaling and root planing (SRP); Gingival crevicular fluid.
References:
1.Chapple IL, Matthews JB. The role of reactive oxygenand antioxidant species in periodontal tissue destruction.Periodontol 2000 2007;43:160-232.
2.SlotsJ.Subgingivalmicroflora and periodontal disease.JClinPeriodontol 1979;6:351-82
3. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993;8(Suppl. 2):S565-S72.
4.Goziotis A, Sukhu B, Torontali M, DowhaniukM,Tenenbaum HC. Effects of bisphosphonates APD andHEBP on bone metabolism in vitro. Bone 1995;
16(Suppl. 4):317S-27S.
5.Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992;13:249-55.
6.Giuliani N, Pedrazzoni M, Negri G, Passeri G, ImpicciatoreM, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promoteearly osteoblastogenesis in young and aged mice in vivo.Bone1998;22:455-61.
7.Vitte´C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast- mediated resorption. Endocrinology 1996;137:2324-33.
8. Yaffe A, Fine N, Alt I, Binderman I. Effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. JPeriodontol 1995;66:999-1003.
9. Yaffe A, Fine N, Binderman I. Regional accelerated phenomenon in the mandible following mucoperiosteal flap surgery. J Periodontol 1994;65:79-83.
10. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, BindermanI. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal
flap surgery in rats. J Periodontol 1997;68:884-9.
11. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing:Literature review and a case report. J Periodontol2007;78:584-94.
12. Silness J, Lo¨e H. Periodontal disease in pregnancy. II.Correlation between oral hygiene and periodontal condition.ActaOdontolScand1964;22:121-35.
13. Lo¨eH ,Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. ActaOdontolScand 1963;21:533-51.
14.Reddy GT, Kumar TM, Veena KM. Formulation and evaluation of alendronate sodium gel for the treatment of bone resorptive lesions in periodontitis. Drug Deliv 2005;12:217-22.
15. Lin JH, Chen IW, deLuna FA.On the absorption of alendronate in rats.JPharmSci1994;83:1741-46.
16. Fleisch H. Bisphosphonates: Mechanisms of action.Endocr Rev 1998; 19:80-100.
17. Srisubut S, Teerakapong A, Vattraphodes T, TaweechaisupapongS. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats.OralSurg Oral Med Oral Pathol Oral Radiol Endod2007;104:e11-e16.
18.Luckman SP, Coxon FP, Ebetino FH, Russell RGG,Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structureactivity relationships inmacrophages. J Bone Miner Res 1998;13:1668-78.
19.Rocha M, Nava LE, Va´zquez de la Torre C, Sa´nchez-Ma´ rin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. JPeriodontol2001;72:204-09.
20.Brunsvold MA, Chaves ES, Kornman KS, Aufdemort TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63:825-30.
21.Needleman IG, Pandya NV, Smith SR, Foyle DM. The role of antibiotics in the treatment of periodontitis J Periodontol • January 2012 Sharma, Pradeep17(part 2 – controlled drug delivery). Eur J ProsthodontRestor Dent 1995;3:111-17.
Article citation:-
Gulri A, Sood R ,Dodwad V & Nagpal S. Clinical efficacy of 1% alendronate gel as a local drug delievery system in the treatment of chronic periodontitis. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1343-1347. Available at http://www.jpbms.info.
Copyright © 2013 Gulri A, Sood R, Dodwad V & Nagpal S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical study
*1Dahiya Swati, 2Gupta Udayan,3Dodwad Vidya,4Kukreja Jha Bhavna & 5 Gupta Das Prafull.
Affiliation:
1Post graduate 3rd year, 2Professor, 3HOD & Professor, 4Senior Lecturer, Department of periodontics, I.T.S-CDSR, Murad Nagar , Ghaziabad, U.P, India.
5Senior Resident, Department of periodontics, KGMC, Lucknow, U.P, India.
Abstract:
Objective: To evaluate the effects of smoking on clinical parameters and enzyme activity of alkaline phosphatase in GCF in patients with chronic periodontitis before and after 30 days of scaling and root planing.
Method: A total of 20 patients (with a pocket depth ≥ 5 mm) were selected for the study. Patients were divided randomly into Test group (n=10) including current smokers and Control group (n=10) including non-smokers. The clinical parameters including plaque index (PI), gingival index (GI), pocket probing depth (PD), clinical attachment level (CAL) were recorded and GCF samples were collected for analysis of Alkaline phosphatase levels before and 30 days after scaling and root planing.
Results: In test group PI, GI (p<0.001) and ALP (p<0.002) levels were found to be statistically significant after scaling and root planing. No statistically significant results were found in relation to PD and CAL(p=0.268 and p=0.703 respectively).
Conclusion: The present study concluded that GI, PI, Pocket Probing Depth, CAL & ALP were reduced in smokers and non smokers after 30 days of initial periodontal therapy. Cigarette smoking has an effect on the levels of ALP in GCF in smokers.
Key Words: Alkailine phosphatase; Gingival crevicular fluid.
References:
1.McCauley LK, Nohutcu RM. Mediators of periodontal osseous destruction and remodeling: Principles and implications for diagnosis and therapy. J Periodontol 2002; 73(11): 1377-9.Pubmed
2.Lamster IB, Harper DS, Goldstein S, Celenti RS, Oshrain RL The effect of sequential sampling on crevicular fluid volume and enzyme activity. J Clin Periodontol 1989; 16: 252-58.Pubmed
3.Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis- a review. J clin Periodontol 2000:27:453-65.Pubmed
4.Jin L, Yu C, Corbet EF. Granulocyte elastase activity in static and flow gingival crevicular fluid. J Periodontal Res 2003; 38: 303-10.Pubmed
5.Kiili M, Cox SW, Chen HW, Wahlgren J, Maisi P, Eley BM, Salo T, Sorsa T. Collagenase-2 (MMP-8) and collagenase- 3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol 2002; 29: 224-32.Pubmed
6.Tsalikis L, Malaka E, Pavlitou E, Konstantinidis A. Aspartate aminotransferase levels in gingival crevicular fluid before and after initial periodontal treatment. J Int Acad Periodontol 2001; 3: 68-4.Pubmed
7.Chapple IL, Garner I, Saxby MS, Moscrop H, Matthews JB. Prediction and diagnosis of attachment loss by enhanced chemiluminescent assay of crevicular fluid alkaline phosphatase levels. J Clin Periodontol 1999; 26: 190-98.Pubmed
8.Ishikawa, Cimasoni G. Alkaline phosphatase in human gingival fluid and its relation to periodontitis. Arch Oral Biol 1970;15: 1401-04.Pubmed
9.Gao J, Symons AL, Haase H, Bartold. Should cementoblasts express alkaline phosphatase activity? Preliminary study of rat cementoblasts in vitro. J Periodontol 1999; 70(9):951-9.Pubmed
10.Shibata Y, Yamashita Y, Miyazaki H, Ueno S, Takehara T. Effective method of disciminatind between oral bacterial and human alkaline phosphatas activity. Oral Microbiol Immunol 1994; 9:35-9.Pubmed
11.Yan F. Alkaline phosphatase level in GCF of periodontitis before and after periodontal treatment. Chung Hua Kou Chiang Tsa Chin. 1995; 30: 255-66.Pubmed
12.Plagnat D, Giannopulou C, Carrel A, Bernad JP, Mombelli A, Belser UC. Elastase, alpha2-macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without peri-implantitis, Clin Oral Implants Res 2002; 13:227-33.Pubmed
13.Gibert P, Tramini P, Sieso V, Piva MT. Alkaline phosphatase isozyme activity in serum from patients with chronic periodontitis. J Periodontal Res 2003; 38: 362-5.Pubmed
14.Feldman RS, Bravacos JS, Rose CL. Associations between smoking different tobacco products and periodontal disease indexes. J Periodontol 1983; 54: 481-87.Pubmed
15.Bergström J, Eliasson S. Cigarette smoking and alveolar bone height in subjects with high standard of oral hygiene. J Periodontol 1987; 14: 466-69.Pubmed
16.Bergström J, Eliasson S. Noxious effect of cigarette smoking on periodontal health. J Periodontal Res 1987; 22: 513-17.Pubmed
17.Bergström J. Cigarette smoking as a risk factor in Chronic periodontal disease. Comm Dent Oral Epidemiol 1989; 17: 245-47.Pubmed
18.Genco RJ, Löe H. The role of systemic conditions and disorders in periodontal disease. Periodontol 2000 1993; 2: 98-116.Pubmed
19.Bergström J, Preber H. Tobacco use as a risk factor. J Periodontol 1994; 65: 545-50.
20.Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, Norderyd OM, Genco RJ. Assessment of risk for periodontal disease.I. Risk indicators for attachment loss. J Periodontol 1994; 65: 260-67.Pubmed
21.Grossi SG, Genco RJ, Machtei EE, Ho AW, Koch G, Dunford R, Zambon JJ, Hausmann E. Assessment of risk for periodontal disease.II. Risk indicators for alveoler bone loss. J Periodontol 1995; 66: 23-29.Pubmed
22.The American Academy of Periodontology. Tobacco use and the periodontal patient (position paper). J Periodontol 1999; 70: 1419-27.Pubmed
23.Persson L, Bergstrom J, Ito H, Gustafsson A. Tobacco smoking and neutrophil activity in patients with periodontal disease. J Periodontol 2001; 72: 90-5.Pubmed
24.Soder B, Jin LJ, Wickholm S. Granulocyte elastase, matrix metalloproteinase-8 and prostaglandin E2 in gingival crevicular fluid in matched clinical sites in smokers and non-smokers with persistent periodontitis. J Clin Periodontol 2002; 29: 384-91.Pubmed
25.CDC.Vital signs: current cigarette smoking among adults aged ≥18 years—United States, 2009. MMWR 2010;59:1135–40.Pubmed
26.Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of vitamin C. J Periodontol 1970;41(1):41-3.Pubmed
27.Loe H, Silness J. Periodontal disease in pregnancy. Acta Odontol Scand 1963; 21:533-535.Pubmed
28.Preber H, Kant T, Bergström J. Cigarette smoking oral hygiene and periodontal health in Swedish army conscripts. J Clin Periodontol 1980; 7: 106-13.Pubmed
29.Linden GJ, Mullally BH. Cigarette smoking and periodontal destruction in young adults. J Periodontol 1994; 65: 718-23.Pubmed
30.Boström L, Linder LE, Bergström J. Influence of smoking on the outcome of periodontal surgery. A 5-year follow-up. J Clin Periodontol 1998, 25: 194-01.Pubmed
31.Axelsson P, Paulander J, Lindhe J. Relationship between smoking and dental status in 35-, 50-, 65-, and 75-year-old individuals. J Clin Periodontol 1998 (4):297-305.Pubmed
32.Van der Weijden GA, de Slegte C, Timmerman MF, van der Velden U. Periodontitis in smokers and non-smokers: intra-oral distribution of pockets. J Clin Periodontol 2001; 28(10):955-60.Pubmed
33.Preber H, Bergström J. The effect of non-surgical treatment on periodontal pockets in smokers and non-smokers. J Clin Periodontol 1985; 13: 319-23.Pubmed
34.Kaldahl WB, Johnson GK, Patil KD, Kalkwarf KL. Levels of cigarette consumption and response to periodontal therapy. J Periodontol 1996; 67: 675-81.Pubmed
35.Pucher JJ, Shibley O, Dentino AR, Ciancio SG. Results of limited non-surgical periodontal therapy in smokers and non-smokers. J Periodontol 1997; 68: 851-56.Pubmed
36.Fedde KN, Cole DE, Whyte MP. Pseudohypophosphatasia: Aberrant localisation and substrate specifity of alkaline phosphatase in cultured skin fibroblasts. Am J Human Gene 1990; 47: 776-83.Pubmed
37.Chapple ILC, Sokransky SS, Dibart S, Glenwright HD, Matthews JB. Chemiluminescent assay of alkaline phosphatase in human gingival crevicular fluid: investigations with an experimental gingivitis model and studies on the source of the enzyme within crevicular fluid. J Clin Periodontol 1996; 23: 587-94.
Article citation:
Dahiya Swati, Gupta Udayan, Dodwad Vidya, Kukreja Jha Bhavna & Gupta Das Prafull. The Enzyme activity of alkaline phosphatase in gingival crevicular fluid of smokers and non-smokers with chronic periodontitis before and after phase I therapy. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1348-1353. Available at http://www.jpbms.info.
Copyright © 2013 Dahiya Swati,Gupta Udayan,Dodwad Vidya,Kukreja Jha Bhavna & Gupta Das Prafull. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report:-
Dhiraj B.Nikumbh1, Priya S.Bagle2,Chakor M.Rokade3, Sashikant Nikam4, Yogesh R.Tayade3
Affiliation:-
1* MD, Associate Professor, 2MD, Assistant Professor, 3MBBS, Assistant Lecturer, Dept Of Pathology, JMF’s ACPM medical college, Dhule, Maharashtra, India.
4 MS, Consultant Surgeon, Private Hospital. Maharashtra, India.
Author’s contribution: - All authors contributed equally to this paper.
Abstract:
Primary adenoid cystic carcinoma (ACC) of the breast is an uncommon histological form of breast cancer accounting for 0.1% of all mammary neoplasm. ACC of the breast has favorable prognosis, contrasting to the aggressive nature of the ACC at other sites like head and face especially salivary gland. It has a biological cancer of slow progression and near absence of lymph nodes metastasis. To date about 150 cases of ACC are reported in literature so far.
We are presenting a case of adenoid cystic carcinoma in a 38 year old female presented with painless mass in right breast. ACC may mimic the most common form that is intraductal carcinoma on clinical, mammography and sonography. Accurate histopathological diagnosis is always warranted, in view of its rare nature but with favorable prognosis. We report this case due to its rarity with good prognostic value if proper and early diagnosed on histopathology.
Key Words: Adenoid cystic carcinoma; breast; mammary neoplasm.
References:
1.Kontos M, Futiman IS. Adenoid cystic carcinoma of the breast. Int J Clinical Pract. 2003;57;667-72.
2.Law Ym, Quck ST, Tan PH, Wang SLJ. Adenoid cystic carcinoma of the breast. Singapore Med J. 2009;50;e8-e11.
3.Peter GN, Wolff M. Adenoid cystic Carcinoma of the breast. Report of 11 new cases: Review of the literature and discussion of biological behaviour. Cancer. 1983;52:680-6.
4.Leeming R, Jenkins M, Mendelson G. :Adenoid cystic carcinoma of the breast .Arch Surg. 1992;127:233-235.
5.Arpino G, Clark GM, Mohsim S, Bardon VJ, Elledge RM:Adenoid cystic carcinoma of the breast :Molecular marker, treatment and clinical outcome.Cancer .2002;94(8) :2119-72.
6.Musthafa S, Musthfa E, Aden H, Ertan B Nashuhi E. Adenoid cystic carcinoma of the breast .Tr. J of Medical Science .1998;28:203-205
7.Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, and Boughey JC. Adenoid cystic carcinoma of the breast. American Journal of Roentgenology. 2010;194(5) :1391-6.
8.Rosen PP. Adenoid cystic carcinoma of the breast: A morphological heterogeneous neoplasm. In: Rosen PP, Fetchner RE, Norwalk CT(eds). Pathology annual 1989;Vol 24 (part 2).Norwalk, CT:Appleton and Lange;1989:P237-54.
9.Stanely MW, Tani EM, Retqwist EL, Stoog L. Adenoid cystic carcinoma of the breast. Diagnosis by fine needle aspiration .Diagnostic Cytopathology 1993;9(2): 184-7.
10.Sheen-chen SM, Eng HL, Chen WJ, Cheng YF, Ko SF. Adenoid cystic carcinoma of the breast. Truly uncommon or early over looked?. Anticancer Research. 2005;25:455-458.
11.Clement PB, Yong RH, Azzorpardi JG: Collogeneous Spherolosis of the breast. Am J Surg Path. 1987; 11:411-7.
12.Rosen PP: Adenoid cystic carcinoma of the breast: a morphologically heterogeneous neoplasm. Pathology Annual. 1989; 24:237-54.
13.Muslimani AA, Ahluwalia MS , Clark CT, Daw HA. Primary Adenoid cystic carcinoma of the breast: Case report and review of the literature. International Seminars in Surgical Oncology. 2006; 3(17):1-4.
Article citation:
Nikumbh DB et al. Primary adenoid cystic carcinoma of the breast. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1378-1380. Available at http://www.jpbms.info.
Copyright © 2013 Nikumbh DB et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
*1Nandedkar Prerna D.,2Sonune Sanjay.,3Chitta Shrinivas S.,4Rajurkar Sampada R
Affiliation:-
1Assistant professor, 2Professor Department of biochemistry,3Junior resident, Department of physiology,4Assistant professor, Department of PSM Government medical college, Akola (M.S), India.
Abstract:
An epidural catheter even after safe insertion & Incidence of chronic kidney disease (CKD) is increasing worldwide and show poor outcome. The correct mechanism responsible for hyperlipidemia in the patients of CKD with NS is not understood. There are very few evidences showing hyperlipidemia in patients of CKD without NS. Therefore present study is undertaken to study lipid profile pattern in CKD and compare lipid profile in CKD with NS and CKD without nephrotic syndrome.
Aims: To estimate and compare lipid profile pattern in patients of CKD with NS and CKD without NS
Settings and designs: This cross sectional study was undertaken in the Department of Biochemistry of Government Medical College Nagpur, Maharashtra.
Material and method and statistical analysis: lipid profile was analyzed and compared between 50 age & sex matched CKD withNS cases (group I) and CKD without NS cases (group II) and normal healthy subjects control of age group 20-60 years using unpaired two‐tailed Student‘t’ test.
Results: Values of total cholesterol (p<0.001), triglyceride (p<0.001), LDL-C (p<0.001) and were significantly higher in CKD with NS (group I) and CKD without NS (group II) as compare to controls but values of HDL-C (p<0.001) were significantly lower compared to controls. Also, Values of total cholesterol (p<0.001), triglyceride (p<0.001), LDL-C (p<0.001) and were significantly higher in (group I) as compared to (group II) but values of HDL-C (p>0.05) were insignificant in (group I) as compared to (group II)
Conclusion: hyperlipidemia causes high cardiovascular risk and futher renal impairement in patients of CKD with NS as compared to CKD without NS.
Key words: (CKD) Chronic kidney disease; Hyperlidemia; (NS) nephrotic syndrome.
References:
1.Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D:Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
2.Kasiske BL. Hyperlipidemia in patients with chronic renal disease:Am J Kidney Dis 1998;32:142-S156.
3.Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206.
4.Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al; The Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 1989;13(Suppl):I80-I93.
5.Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
6.Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
7.Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease: J Am Soc Nephrol 1998;9(12 Suppl): S16-23.
8.IBM SPSS Statistics [computer program].Version 19.0.0. Somers (NY): IBM
9.Antonio Lacquaniti Davide Bolignano Tsimihodimos V, Dounousi E, Siamopoulos KC: Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958–73.
10.Khanna UB, Nerurkar SV, Almeida AF, Taskar SP, Acharya VN:Study of hyperlipidemia in adults with nephrotic syndrome. J Postgrad Med 1985;31:140.
11.CM Chan: Hyperlipidaemia in Chronic Kidney Disease; Ann Acad Med Singapore 2005;35:31-5.
12.Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ: Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003; 84:121–4.
Article citation:-
Nandedkar Prerna D.,Sonune Sanjay., Chitta Shrinivas S., Rajurkar Sampada R. Comparative study of hyperlipidemia in patients of CKD with nephrotic syndrome and CKD without nephrotic syndrome. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1396-1399.Available at http://www.jpbms.info.
Copyright © 2013 Nandedkar Prerna D.,Sonune Sanjay.,Chitta Shrinivas S.,Rajurkar Sampada R.. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report:-
Quadros Lydia S1*, Babu Arathy2, Bhat Nandini2, Ankolekar Vrinda Hari3
& D’souza Antony S4.
Affiliation:-
1*M.Sc.(Medical), 2Post graduates, 3MD Anatomy, 4MS Anatomy,Department of Anatomy, Kasturba Medical College, Manipal University, Madhavnagar, Manipal, Karnataka, India. – 576104.
Abstract:
A variation in the course and branches of the maxillary artery is well documented. In the present case, we came across variations in the branching pattern of the first and second parts maxillary artery in the right infratemporal fossa. It was noted that the Middle meningeal and accessory meningeal arteries took origin from the second part of maxillary artery and the deep temporal arteries aroused from the first part in common with the inferior alveolar artery and also from the second part of the maxillary artery. The second part of maxillary artery and its branches passed deep to the lateral pterygoid muscle and superficial to the branches of mandibular nerve. Rest of the branches had a normal origin. Such variations are of clinical importance for the surgeons in performing surgeries and also for the radiologists in interpretation of the radiological images.
Key Words: Infratemporal fossa; intra-arterial chemotherapy; maxillary artery.
References:
1.Uysal II, Buyukmumcu M, Dogan NU, Seker M, Ziylan T. Clinical significance of maxillary artery and its branches: A cadaver study and review of the literature. Int. J. Morphol. 2011; 29(4):1274-81.
2.Bergmann RA, Thompson SA, Afifi AK and Saadeh FA. Compendium of Human Anatomic Variation: Catalog, Atlas and World literature. Urban &Schwarzenberg, Baltimore and Munich.
3.Harn SD, Durham TM. Anatomical variations and clinical implications of the atery to the lingual nerve. Clinical Anatomy 2003, 16:294-9.
4.Pretterklieber ML, Skopakoff C, Mayr R. The human maxillary artery reinvestigated: Topographical relations in the infratemporal fossa. ActaAnat (Basel) 1991, 141(4):281-7.
5.HurMi-Sun, Kim Ho-Jeong, Lee Kyu-Seok. Unusual course of the accessory meningeal artery. Korean J PhysAnthropol 2012, 25(4):193-6.
6.Kumar S, Mishra NK. Middle meningeal artery arising from the basilar artery: Report of a case and its probable embryological mechanism. J NeuroInterventSurg doi:10.1136/jnis.2010.004465.
7.Shah QA, Hurst RW. Anomalous origin of the middle meningeal artery from the basilar artery: A case report. J. Neuroimaging 2007, 17(3):261-3.
8.Kuruvilla A, Aguwa AN, Lee AW, Xavier AR. Anomalous origin of middle meningeal artery from the posterior inferior cerebellar artery. J Neuroimaging 2007, 21(3):269-72.
9.Suwa F, Takemura A, Ehara Y, Takeda N, Masu M. On the arteriamaxillaris which passes medial to the pterygoideuslateralis muscle of the Japanese: patterns of origin of the inferior alveolar, the masseteric and the posterior temporal arteries. Okajimas Folia AnatJpn 1990 Dec, 67(5):303-8.
Article citation:-
Quadros Lydia S et al. Anatomical variations in the branches of maxillary artery: A case report. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013, July; 32(32): 1271-1273. Available at http://www.jpbms.info.
Copyright © 2013 Quadros Lydia S et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.